References

  1. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 9(12): 1191-1197, 2008.
  2. Yancik R: Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 Suppl): 517-23, 1993.
  3. American Cancer Society: Cancer Facts & Figures 2018. Atlanta, GA: American Cancer Society, 2018. Available from https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.htmlExternal Website Policy
  4. American Joint Committee on Cancer: AJCC Cancer Staging Manual(8 ed.). Chicago, IL: American Joint Committee on Cancer, 2017.
  5. Genetic and Rare Diseases Information Center: Fallopian Tube Cancer. Gaithersburg, MD: National Institutes of Health, 2015. Available from https://rarediseases.info.nih.gov/diseases/9162/fallopian-tube-cancer
  6. Surveillance, Epidemiology, and End Results Program: Cancer Stat Facts: Ovarian Cancer. Bethesda, MD: National Institutes of Health, 2016. Available from https://seer.cancer.gov/statfacts/html/ovary.html
  7. Howlader N, Noone AM, Krapcho M, Miller D, Dishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA: SEER Cancer Statistics Review, 1975-2015, Bethesda, MD, 2017.
  8. Aarnio M, et al.: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2): 214-8, 1999.
  9. Watson P, et al.: The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123(2): 444-449, 2008.
  10. Pearce CL, et al.: Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4): 385-94, 2012.
  11. Modugno F, et al.: Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 191(3): 733-40, 2004.
  12. Miki Y, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182): 66-71, 1994.
  13. Wooster R, et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559): 789-92, 1995.
  14. La Vecchia C: Ovarian cancer: Epidemiology and risk factors. Eur J Cancer Prev 26(1): 55-62, 2017.
  15. National Cancer Institute: Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ) - Health Professional Version. Bethesda, MD: National Institutes of Health, 2018. Available from https://www.cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq
  16. Heintz AP, et al.: Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1): S161-92, 2006.
  17. Prat J: Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1): 1-5, 2014.
  18. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer(Version 2). Fort Washington, PA: National Comprehensive Cancer Network, 2018.
  19. National Cancer Institute: Cancer Trends Progress Report. Bethesda, MD: National Institutes of Health, 2018. Available from https://progressreport.cancer.gov/treatment/ovarian_cancer#field_data_source

Updated: June 8, 2018